Physician profile
Mary J Strength
NPI 1730203126
$4,407.48
in general payments reported to CMS, 2019-2025
20 companies · $447 in 2025
The $447 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $277 · 2021: $1,049 · 2022: $501 · 2023: $531 · 2024: $695 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $904.08 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $727.97 | 2021-2024 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $674.99 | 2019 | |
| Tris Pharma INC | $497.02 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $458.03 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $161.69 | 2025 | Jornay Pm |
| Gm Pharmaceuticals, INC. | $145.10 | 2024 | Vanacof |
| Cranial Technologies, INC | $130.22 | 2019-2025 | Doc Band |
| Sanofi Pasteur INC. | $123.81 | 2021-2024 | |
| Pfizer INC. | $98.98 | 2019-2023 | |
| Glaxosmithkline, LLC. | $79.30 | 2022-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $78.05 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $72.22 | 2020-2021 | |
| Seqirus USA INC | $62.10 | 2022-2024 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $52.65 | 2019-2024 | Relexxii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $47.27 | 2019 | |
| Adlon Therapeutics L.P. | $32.30 | 2019 | |
| Alk-Abello, INC | $23.41 | 2024 | Odactra, Grastek, Ragwitek |
| Acadia Pharmaceuticals INC | $22.78 | 2023 | Daybue |
| Genentech USA, INC. | $15.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Strength listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.